Trial Profile

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amfetamine (Primary)
Indications Attention-deficit hyperactivity disorder
Focus Registrational; Therapeutic Use
Sponsors Tris Pharma

Most Recent Events

05 Aug 2025 According to Kye Pharmaceuticals Inc. media release, the company announced the Health Canada approval (notice of compliance) for Dyanavel XR (amphetamine extended-release) tablets and oral suspension for the treatment of ADHD in adults and children.
22 Jul 2022 Results published in the Tris Pharma Media Release.
22 Jul 2022 According to a Tris Pharma media release, study results were published in the Journal of Clinical Psychiatry.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com